<DOC>
	<DOC>NCT02548455</DOC>
	<brief_summary>The primary intent of this study is to assess the safety of the model 1457Q Quartet Left Ventricular (LV) lead at 3 months in a patient population indicated for cardiac resynchronization therapy.</brief_summary>
	<brief_title>St Jude Medical LV Lead - Quartet 1457Q IDE</brief_title>
	<detailed_description>This is a prospective, multi-center, IDE clinical study designed to evaluate the safety of the Model 1457Q Quartet LV lead. A minimum of 94 and a maximum of 430 subjects will be enrolled in this study at up to 40 centers worldwide. All subjects successfully implanted with a Quartet 1457Q lead will be followed every 6 months post implant until Pre Market Approval (PMA) is obtained or the study is closed. After completing participation in the IDE study, subjects will continue participation in a post-approval study, and return for follow up visits every 6 months post implant until 5 years of follow up visits post implant are completed.</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
	<criteria>1. Meets current SJM clinical indication for implantation of a CRT system: " to provide a reduction of the symptoms of moderate to severe heart failure (New York Heart Association Functional Class III or IV) in those patients who remain symptomatic despite stable, optimal medical therapy and have a left ventricular ejection fraction â‰¤ 35% and a prolonged QRS duration, OR " to maintain synchrony of the left and right ventricles in patients who have undergone an Atrio Ventricular nodal ablation for chronic (permanent) atrial fibrillation and have New York Heart Association Functional Class II or III heart failure. 2. Is receiving a new marketapproved SJM Quadripolar CRT system implant with the Model 1457Q Quartet LV lead. 3. Have the ability to provide informed consent for study participation and is willing and able to comply with the prescribed followup tests and schedule of evaluations. 4. Are 18 years or above, or of legal age to give informed consent specific to state and national law. 1. Had a previous unsuccessful commercial or nonQuartet 1457Q LV lead implant attempt 2. Have a hypersensitivity to a single 1.0mg dose of dexamethasone sodium phosphate 3. Patient is currently participating or plans to participate in a potentially confounding drug or device trial during the course of this study. Coenrollment in other studies may be allowed if preapproval is granted from the study manager. 4. Are pregnant or planning pregnancy in the next 6 months 5. Have a life expectancy of less than 24 months due to any condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>